Simris Group AB

Simris Group AB is a pioneering biotechnology company dedicated to the research, development, and production of bioactive substances sourced from cyanobacteria and microalgae for groundbreaking pharmaceutical applications. With a commitment to innovation, Simris Group AB is at the forefront of developing the next generation of Antibody Drug Conjugate (ADC) payloads, poised to revolutionize cancer treatment. Their headquarters are located in Hammenhög, Skåne, Sweden, at Herrestadsvägen 24A, 276 50. An additional location is situated in Berlin, Germany, at Magnusstraße 11, 12489.

Simris Group AB's platform is built upon the world's largest cyanobacterial strain library, cultivated over two decades of profound scientific expertise. Leveraging proprietary discovery and bioconjugation technologies, Simris Group AB is diligently creating novel, IP-protected payloads that hold the potential to significantly enhance both the efficacy and safety of ADC therapeutics. Simris Group AB stands as a public company, with its stock traded on the Nasdaq First North stock exchange (FNSE:SIMRIS B), reflecting its dedication to transparency and growth.

Simris Group AB continues to drive advancements in biotechnology. The team remains focused on delivering innovative solutions for pharmaceutical applications, particularly in the realm of cancer treatment. We encourage the management team at Simris Group AB to create a customized and exclusive company showcase and product listing on our platform to further highlight your exceptional work.